Filtered by tag "CBD"

Retail Momentum Gathers for CBD Topicals While FDA Decides Its Direction

By William Sumner, Hemp Business Journal Contributor Hemp-derived CBD is all the rage right now, even as confusion and illegality abound. Prompted by the passage of the 2018 Farm Bill, which legalized hemp and hemp derivatives like CBD, investors and entrepreneurs have been scrambling to capitalize on the increasingly popular substance. The United States Food and Drug Administration […]
Read more

More Growth, Consolidation, and M&A Expected for Hemp Industry in 2019

By William Sumner, Hemp Business Journal Contributor From acquisitions to equity investments, the North American hemp industry has been awash in capital investment since the Farm Bill 2018 was federally passed in the United States last December. In the rush for first-mover advantages, entrepreneurs and investors have been scrambling for respective footholds in the nascent hemp market; even [...]
Read more

EFSA’s CBD Novel Food Classification

By Bill Griffin New Frontier Data contributor The emerging European cannabidiol (CBD) market has been thrown into disarray since January 2019 over a change to CBD’s classification by the European Food Safety Authority (EFSA). Here we look at what changed and explore options for those companies impacted. What changed? Before January 2019, the entry for […]
Read more

As Summer Heats Up, So Too Does Market Buzz About Hemp and CBD Products

By William Sumner, Hemp Business Journal Contributor, and J.J. McCoy, Senior Managing Editor, New Frontier Data The Fourth of July is traditionally a time of celebration without partisanship, a national holiday marked by firing up the grill, watching fireworks, and commemorating the founding of the United States. Less familiar are the ways by which hemp was historically utilized […]
Read more

European Hemp Market Offers Major Obstacles Along with Speculative Rewards

By William Sumner, Hemp Business Journal Contributor While much has been made about the nascent hemp markets in the United States and Canada, the European market has proven to be enticing on its own: The Hemp Business Journal estimates that by 2020 Europe will see approximately $1.5 billion in sales, whereas the U.S. market is respectively expected to […]
Read more

Discretionary Consumption Becomes Law in the Land of Lincoln

By Larry Mishkin, Hoban Law Group, Litigation Practice Group Counsel Last month, the Illinois legislature sent an adult-use cannabis bill to new governor Jay Pritzker for signature. Given all indications that he will sign it, legal discretionary use in Illinois will begin on January 1, 2020. Significantly, passage will mark the Prairie State as the […]
Read more

Discretionary Consumption Becomes Law in the Land of Lincoln

By Larry Mishkin, Hoban Law Group, Litigation Practice Group Counsel Last month, the Illinois legislature sent an adult-use cannabis bill to new governor Jay Pritzker for signature. Given all indications that he will sign it, legal discretionary use in Illinois will begin on January 1, 2020. Significantly, passage will mark the Prairie State as the […]
Read more

Much About CBD Remains TBD as FDA Crafts Food, Supplements Policy

By William Sumner, Hemp Business Journal Contributor While federal regulators consider whether to classify cannabidiol (CBD) as a pharmaceutical ingredient or allow its use as a nutritional supplement, individual states are making moves to decide the issue for themselves. In the state of California, a bill is working its way through the state legislature to make it legal […]
Read more

With Legalization, Illinois Leaps Headlong into the Industrial Hemp Market

By William Sumner, Hemp Business Journal Contributor Illinois is going all-in on cannabis. In becoming the first state to legislatively enact (rather than pass via ballot measure) both to legalize adult-use cannabis and create a state sales marketplace, Illinois has seen a surge in interest for industrial hemp. Prompted by the passage of the 2018 Farm Bill, which […]
Read more

FDA Public Hearing About CBDs Prescribes Caution, Bearishness, and Deliberation

By William Sumner, Contributing Writer for the Hemp Business Journal Last Friday, the U.S. Food and Drug Administration (FDA) held its first public hearing about the safety and regulation of cannabis and cannabis-derived products. At the heart of the hearing were issues of how the FDA should regulate CBD, which has been growing in popularity as […]
Read more
Top